Nymox reports new positive results from BPH study

The study evaluated symptomatic progress of US patients involved in the company’s two initial 2003 Phase I-II studies of NX-1207. Patients treated with NX-1207 were followed-up on an unselected and as available basis and assessed for symptomatic improvement, treatment outcomes, and durability of efficacy 64 months after treatment.

Data was available for 75% of the subjects in the initial studies. Overall, 67% of the patients in the new outcome study treated with NX-1207 reported no current drug treatment for their benign prostatic hyperplasia (BPH) and had a mean improvement of 11 points in American Urological Association symptom score, the company said.

In addition, 46% of the patients reported no other approved treatments at any time for their BPH since their original treatment with NX-1207, with a mean improvement of 13 points. This sustained improvement in BPH symptom score after NX-1207 treatment compares favorably to the 3.5 to five points reported in published studies of currently approved BPH drugs, which, unlike NX-1207 treatment, require uninterrupted, daily administration to be effective, according to the company.

NX-1207 has entered its Phase III development program, the last stage before filing with the FDA for approval.